Nasdaq:US$20.17 (-0.79) | HKEX:HK$31.70 (-1.70) | AIM:£3.24 (-0.13)
上一篇文章   |   下一篇文章
公告及新聞稿, 監管通知 | 2017-08-18

Directors’ Share Dealing

London: Friday, August 18, 2017: Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) has received notifications that:-

(a) Mr Simon To, Executive Director and Chairman, through Wencheng Capital Limited (“WCL”), a person closely associated (“PCA”) with Mr To, purchased a total of 4,900 American Depositary Shares of the Company (“ADSs”, each representing one half of one ordinary share of US$1.00 each in the capital of Chi-Med) on August 15, 2017 at a price of US$24.50 per ADS. WCL is controlled by the trustee of Wencheng Trust (“WT”) which has been established for the benefit of Mr To’s family member, of which Mr To is the settlor; and

(b) Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 5,336 ADSs at an average price of US$24.92 per ADS on August 16 and 17, 2017.

Following the above purchases, (i) Mr To is interested in 118,489 ADSs (in Dynamic Drive Trust (“DDT”) and WT of which his family members are the beneficiaries) and 180,000 Ordinary Shares (including the holding of 78,000 Ordinary Shares in DDT of which his family members are the beneficiaries), representing in aggregate approximately 0.39% of the current issued share capital of Chi-Med; and (ii) Ms Shih is interested in 96,000 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.

Please download the full announcement for the notifications as provided in accordance with the requirements of the EU Market Abuse Regulation.